BioPharma Dive - Latest News

Third Harmonic outlines plans for dissolution

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it pursued after halting work on a different immune drug in 2022.

Apr 14, 2025 - 17:02
 0
Third Harmonic outlines plans for dissolution

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it pursued after halting work on a different immune drug in 2022.

Read More

Tags:

Previous Article

First Class Used To Be Free With Status—Now I Use A $70/Hour Rule For Discounted...

Next Article

Strategies toward high-energy-density Co-free lithium nickel manganese oxide: fr...

Related Posts

US risks losing biotech edge to China, report warns

US risks losing biotech edge to China, report warns

Apr 8, 2025  0

A brain biotech launches with Roche’s spare parts

A brain biotech launches with Roche’s spare parts

Feb 13, 2025  0

Trump orders agencies to plan for ‘large-scale’ job cuts

Trump orders agencies to plan for ‘large-scale’ job cuts

Feb 12, 2025  0